Assessing the Options for Pharmacare Reform in Canada

The Conference Board of Canada, 58 pages, November 1, 2018
Report by , ,
5.0/5 based on 3 reviews
(You must be signed in and entitled to rate this report)

National pharmacare has once again arisen as a major issue in Canada. This report assesses five models for achieving universal coverage against how well they might improve access to medicines, value for money, and the patient and provider experience.

Document Highlights

Over the past several decades, numerous options for pharmacare reform in Canada have been studied and discussed. In the course of this debate, there have been many ideas and little consensus.

At present, almost every Canadian is enrolled in or eligible for some form of publicly funded prescription drug coverage. However, this coverage varies considerably across regions and can be confusing for patients, caregivers, and prescribers. Every province and territory has asserted their jurisdiction over health care and developed their own unique publicly funded prescription medication insurance plans.

This report reviews several major proposed models for pharmacare reform as part of The Conference Board of Canada’s National Pharmacare Initiative.

Table of Contents

Assessing the Options for Pharmacare Reform in Canada

  • Executive Summary
  • Setting the Context
  • What Is Universality?
  • Assessing Different Models for Pharmacare Reform
  • Criteria for Assessing Different Models
  • Model 1: Universal Public Coverage
  • Model 2: Targeted Public Coverage
  • Conclusion

Appendix A—Bibliography

COVID-19: Get all the insights

Price: $0

No charge, funded by The Conference Board of Canada and/or the research sponsor

Browse by...
Need Help?